The company's devices, BioZorb Marker and BioZorb LP Marker, are implanted in soft tissue, including breast tissue, where the site needs to be marked for future procedures, such as radiation for breast cancer treatment. The Food and Drug Administration said it has received reports on complications related to the use of the devices in breast tissue including infection, fluid buildup, device moving out of its position and breaking through the skin. It has also received reports of pain, discomfort from feeling the device in the breast along with the need for additional medical treatment for the removal of the device.
Clearbridge Investments LLC bought a new position in Hologic, Inc. (NASDAQ:HOLX – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 365,960 shares of the medical equipment provider’s stock, valued at approximately $25,398,000. Clearbridge Investments LLC owned about 0.15% of Hologic […]
Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 505.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 258,599 shares of the medical equipment provider’s stock after acquiring an […]
Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 505.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 258,599 shares of the medical equipment provider’s stock after buying an […]
EPG Wealth Management LLC bought a new stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,105 shares of the medical equipment provider’s stock, valued at approximately $771,000. Other institutional investors and […]